MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Caladrius Biosciences Total Non Current Liabilities 2011-2025 | CLBS
Annual Total Non Current Liabilities Caladrius Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 254 K | 624 K | 1.51 M | 3.87 M | 28.3 M | 12.9 M | 52 M | 18 M | 11.6 M | 38.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52 M | 254 K | 16.8 M |
Quarterly Total Non Current Liabilities Caladrius Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.4 M | - | - | - | 33.9 M | - | - | - | 68.2 M | - | - | 27.3 M | 27.8 M | 12.6 M | 12.2 M | 27.8 M | 21.6 M | 11.6 M | 11.6 M | 11.6 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 68.2 M | 11.6 M | 26.9 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
81.7 B | $ 223.01 | -0.99 % | $ 395 B | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
5.95 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
30.8 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
9.03 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
BioVie
BIVI
|
62.5 K | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
65.4 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
5.46 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
107 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
58.1 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Cellectar Biosciences
CLRB
|
422 K | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 0.29 | -5.01 % | $ 631 M | Israel |
 |
Cortexyme
CRTX
|
208 K | - | -1.05 % | $ 67.1 M | USA |
 |
Benitec Biopharma
BNTC
|
213 K | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
275 M | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Deciphera Pharmaceuticals
DCPH
|
15.9 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
802 M | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
218 M | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
5.24 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |